CRISPR Therapeutics AG

🇺🇸NASDAQ Global Market
Back to all articles
CRISPR Therapeutics AG stock analysis CRSP overview
Slightly Bullish +25

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

📈 CRISPR Therapeutics shares rose 1.4% over the past month, underperforming the S&P 500's 11% gain and the broader Medical-Biotechnology industry's 1% loss.

🤖 The Zacks investment model prioritizes earnings estimate revisions as the primary driver for short-term stock price movements.

📉 For the current quarter, analysts project a loss of $1.11 per share, representing a +14% improvement from the prior-year period.

📈 Full-year consensus earnings estimates stand at -$5.07, reflecting an +116.2% year-over-year change based on revised growth projections.

💰 Estimates for the next fiscal year show a projected profit of $4.35 per share, indicating a +142% increase from last year's figures.

📉 Earnings estimate trends over the last 30 days indicate a -3.5% revision for the current fiscal year and a -2.7% revision for the next fiscal year.

🧮 The reported revenue of $1.46 million in the last quarter represents a +67.8% increase but missed the consensus estimate by -82.62%.

💰 Previous quarterly earnings per share were -$1.28, compared to -$1.58 a year ago, with EPS estimates missing expectations by -12.28%.

⚖️ The company has surpassed consensus EPS estimates twice in the last four quarters but has not topped revenue estimates during that same period.

📉 A Zacks Rank #3 (Hold) has been assigned to CRSP, suggesting it may perform in line with the broader market in the near term.

💸 The stock received an F-grade on the Zacks Value Style Score, indicating it is currently trading at a premium relative to its peers.

🔭 Revenue estimates for the current quarter and next fiscal year are projected to grow significantly by +818.8% and +274.1% respectively.

📊 The article notes that high revenue growth is essential for sustained earnings expansion in biotech companies like CRISPR Therapeutics.

🧬 Zacks Investment Research recommends checking their proprietary analysis tools for deeper insights into valuation metrics before investing.

Bullish Signals
  • CRISPR Therapeutics showed significant earnings improvement with an expected loss of $1.11 per share for the current quarter, representing a +14% change from the year-ago quarter.
  • The consensus earnings estimate for the fiscal year has improved significantly with a +21.6% year-over-year change to -$5.07, reflecting growing analyst optimism about future profitability.
  • Forward-looking revenue estimates are extremely positive, with current quarter sales projected at $8.18 million and a massive +818.8% increase compared to the same period last year.
  • The company has demonstrated a history of outperforming consensus on EPS estimates twice over the last four quarters and has also topped revenue estimates during this period.
  • Recent reported revenues of $1.46 million grew by +67.8% year-over-year, indicating strong top-line momentum even while operating at a loss.
  • Management has shown confidence in future growth as evidenced by forward fiscal year revenue estimates reaching $129.55 million, a +274.1% increase over the prior year.
  • The company successfully turned its EPS loss from -$1.58 to -$1.28 in the last reported quarter, narrowing the deficit while still scaling up revenue operations.
Risk Factors
  • The stock has significantly underperformed the broader market and its industry peers, gaining only +1.4% over the past month while the S&P 500 rose 11% and the medical-biotech sector lost 1%.
  • CRISPR Therapeutics recently posted a negative earnings surprise of -12.28% and revenue missed consensus estimates by -82.62%, indicating potential issues in meeting investor expectations despite high growth projections.
  • The company is graded F on valuation metrics, signaling that the stock is trading at a significant premium compared to its peers and potentially overvalued relative to its current financial reality.
  • Despite showing improved earnings projections for future periods, the Zacks Rank remains #3 (Hold), suggesting the market expects the stock's near-term performance to merely align with average broader market movements rather than outperform.
Full Analysis
CRISPR Therapeutics AG (CRSP) is described as a trending stock on Zacks.com, with shares having gained 1.4% over the past month compared to the S&P 500's 11% gain and contrasting with its medical genetics industry peers which lost 1%. The article focuses on fundamental factors driving buy-and-hold decisions rather than short-term rumors, emphasizing that fair value is determined by future earnings streams as assessed by sell-side analyst estimate revisions. For the current quarter, CRSP is projected to post a loss of $1.11 per share, representing a 14% improvement from the prior year, while consensus earnings estimates for the quarter have risen 5.9% over the last month; however, full-year estimates decreased by 3.5%, and next fiscal year estimates dipped 2.7% recently, resulting in a Zacks Rank of #3 (Hold) which suggests near-term performance may align with the broader market. Revenue analysis reveals significant growth projections, with consensus sales for the current quarter estimated at $8.18 million, an 818.8% year-over-year increase, and full-year estimates of $34.63 million reflecting an 886.5% jump; historically, the company reported $1.46 million in revenue last quarter with a 67.8% annual increase, though recent results missed consensus expectations by 82.62% on revenue and 12.28% on EPS. Over the last four quarters, CRSP has topped consensus earnings estimates twice and revenue estimates an unspecified number of times, demonstrating a history of occasional outperformance despite current valuation concerns. Valuation metrics indicate that CRSP trades at a premium relative to its peers, receiving a low Zacks Value Style Score of F based on traditional and unconventional valuation multiples like price-to-earnings and price-to-sales ratios. While the article notes that past earnings surprises suggest potential for future outperformance, the combined Zacks Rank and high valuation score lead to the conclusion that investors should be cautious about immediate market buzz, as the stock may simply perform in line with general market trends in the near term until these fundamental drivers shift favorably. The piece concludes by directing readers to Zacks Investment Research for further analysis and free reports on recommended stocks for the next 30 days.